Merck Message Board - Msg: 6768442

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 113.41

+2.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sonki who wrote (1094)	12/10/1998 5:06:00 AM
From: Anthony Wong	Read Replies (1) of 1580

Sonki, you're right about the doom and gloom, and Merck's "warning" (about profits on the low side of analyst estimates) has more to do with their having to spend more money hiring sales reps etc. to step up their sales efforts than a ominous sign of other co. slowing down. Almost everyone of the big phamas has these kinds of corrections (WLA earlier on in the year and a few days ago due to Rezulin, LLY a few months earlier on disappointment of Evista sales, PFE on the Viagra associated deaths etc.) and they've all recovered. I would be interested in buying Merck at some point next year. I'll like to see how Celebrex is doing in the market place first, whether sales of the first Cox-2 inhibitor meet analysts' high expectations. Merck has a lot of challenges ahead of them - patent expirations, Zocor losing market share to Lipitor ( prescriptions"levelling"), their 5 new drugs introcued this year not doing as well as expected. If Vioxx doesn't get priority review status, it would be a great disappoitment for Merck. Anthony

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next